Literature DB >> 5358212

Preliminary clinical trial and the physiologic disposition of 4(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide in man.

J L Skibba, G Ramirez, D D Beal, G T Bryan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 5358212

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  6 in total

1.  Long-term depression of two primary immune responses induced by a single dose of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC).

Authors:  P Puccetti; A Giampietri; M C Fioretti
Journal:  Experientia       Date:  1978-06-15

2.  Clinical pharmacokinetics of high-dose DTIC.

Authors:  J M Buesa; E Urréchaga
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 3.  N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors:  D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules.

Authors:  H Breithaupt; A Dammann; K Aigner
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 5.  WITHDRAWN: Systemic treatments for metastatic cutaneous melanoma.

Authors:  Tom Crosby; Reg Fish; Bernadette Coles; Malcolm Mason
Journal:  Cochrane Database Syst Rev       Date:  2018-02-07

6.  Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells.

Authors:  S M Lee; N Thatcher; M Dougal; G P Margison
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.